Brokerages Set Blueprint Medicines Co. (NASDAQ:BPMC) PT at $71.72

Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) has earned a consensus rating of “Hold” from the twenty brokerages that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, five have given a hold rating, six have given a buy rating and one has given a strong buy […]

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,China ,Nicholasb Lydon ,Chris Varma ,Raymond James ,Stifel Nicolaus ,Jeffreyw Albers ,Brian Druker ,Christina Rossi ,Needham Company ,Affinity Asset Advisors ,Nasdaq ,Blueprint Medicines Co ,China Universal Asset Management Co ,Securities Exchange Commission ,Associates Corp ,Barclays ,Morgan Stanley ,Blueprint Medicines Corp ,Lazard Asset Management ,Blueprint Medicines ,Get Rating ,Marketbeat Ratings ,Exchange Commission ,Director Jeffrey ,Universal Asset Management ,Asset Management ,Alexis Borisy ,Blueprint Medicines Daily ,Nasdaq Bpmc ,Bpmc ,Medical ,Ratings ,Consensus ,